Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

DSIP (delta sleep-inducing peptide): does it work, is it legal, and what does it cost?

A 9 amino acid peptide with small, mixed 1980s insomnia trials; its nomination was withdrawn, and FDA's July 2026 briefing recommended against listing it.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

Quick answers

Quick answers about DSIP (delta sleep-inducing peptide)
Does it work in people?Evidence: Human RCT evidence

At least one randomized human trial in PubMed. See the evidence

Is it legal?Regulatory: Nomination withdrawn

Not FDA approved and not on FDA's list of substances pharmacies may compound (the 503A bulks list), so a pharmacy has no federal basis to compound it. [5] [11] See legal status

What does it cost?Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.
Side effects?No adverse effects beyond placebo were reported in the small trials, but total human exposure is a few dozen patients. Headache and drowsiness reported anecdotally. Injection site reactions reported anecdotally. See side effects and interactions
Tested athlete?WADA: WADA prohibited

What is DSIP (delta sleep-inducing peptide)?

DSIP (delta sleep-inducing peptide) is a nine amino acid peptide isolated in 1977 from blood draining the brains of rabbits in induced sleep and later found in humans. Three small double blind trials (neither patients nor researchers knew who got the peptide) in chronic insomnia in the late 1980s and early 1990s gave inconsistent results, with modest changes in sleep on some measures and none on others, and a 2006 review concluded its role in the body is still unresolved. It is not FDA approved; FDA removed it from the 503A Category 2 list (compounding ingredients flagged for significant safety risks) on April 22, 2026, and when FDA presented it to the Pharmacy Compounding Advisory Committee (FDA's outside expert panel) on July 24, 2026, FDA's own briefing recommended against adding it to the 503A bulks list (ingredients pharmacies may use to compound drugs for individual patients). FDA has not posted the committee's vote.

DSIP (delta sleep-inducing peptide) is an endogenous nonapeptide (9 amino acids) first isolated from the cerebral venous blood of rabbits during induced sleep. It is also known as Delta sleep-inducing peptide, Emideltide, DSIP peptide, Deltaran.

How does it work?

Uncertain. DSIP does not bind a known dedicated receptor. Proposed actions include modulation of GABAergic and glutamatergic transmission, effects on the hypothalamic pituitary axis (it lowers stress induced ACTH and cortisol release in some animal studies), and influence on the circadian regulation of slow wave sleep. Its very short plasma half life and poor blood brain barrier penetration raise doubts about how injected DSIP acts on the brain at all.

Key facts
ClusterOther peptides
RoutesIntravenous infusion (clinical trials); Subcutaneous injection (as sold, no human data); Intranasal (as sold, no human data)
Conditions studiedSleep disorders
Recordv3, reviewed, verified Sep 30, 2026

What does the evidence say about DSIP (delta sleep-inducing peptide)?

Evidence: Human RCT evidenceGrade assigned per the methodology.

Evidence is limited to small double blind placebo controlled trials from 1987 to 1992 in chronic insomnia, none larger than a few dozen patients. Schneider-Helmert 1987 reported improved 24 hour sleep wake behavior in severe chronic insomnia; Monti 1987 found only short lived effects; Bes 1992 found effects that did not persist and were inconsistent across measures. No modern trial exists, and a 2006 review called DSIP an unresolved riddle. Human evidence is therefore graded as randomized but weak, old, and unreplicated.

Indexed studies by evidence grade
Evidence typeIndexed studiesParticipants (human)
Human randomized trials3n/a
Human observational studies1n/a
Animal studies0n/a
All indexed studies4n/a

Human evidence

Schneider-Helmert 1987: severe chronic insomnia patients given intravenous DSIP in a double blind crossover design showed improvements in sleep efficiency and daytime alertness. Monti 1987: chronic insomniacs given DSIP for several nights showed some improvement in sleep latency early in treatment that was not sustained. Bes 1992: double blind study in chronic insomnia found small effects on some polysomnographic measures with no consistent overall benefit. No dose response, long term, or oral study exists, and no trial has tested the subcutaneous form sold today.

Animal evidence

In rabbits and rats, DSIP infused into the brain or bloodstream increased delta (slow wave) EEG activity in some experiments and not in others; the original sleep inducing effect was difficult to replicate across laboratories. Rodent studies also report reduced stress hormone release, antioxidant effects, and anticonvulsant activity. The animal literature is decades old and contradictory.

Key studies

Indexed studies of DSIP (delta sleep-inducing peptide)
StudyDesign and populationOutcomeGrade
Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia1987 PMID 3622582Double blind placebo controlled crossover studyAdults with severe chronic insomniaIntravenous DSIP improved sleep efficiency and daytime performance measures relative to placebo in a small sampleEvidence: Human RCT evidence
Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs1987 PMID 3583493Double blind placebo controlled short term studyAdults with chronic insomniaEarly improvement in sleep latency that was not sustained across the treatment periodEvidence: Human RCT evidence
Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study1992 PMID 1299794Double blind placebo controlled polysomnographic studyAdults with chronic insomniaSmall changes on some polysomnographic measures with no consistent overall improvement in sleepEvidence: Human RCT evidence
Delta sleep-inducing peptide (DSIP): a still unresolved riddle2006 PMID 16539679Narrative reviewAnimal and human literature 1977 to 2005Concludes that DSIP's sleep promoting role is unproven and its receptor and physiological function remain unknownEvidence: Human observational evidence

Conditions studied

Conditions with evidence for DSIP (delta sleep-inducing peptide)
ConditionGradeNote
Sleep disordersEvidence: Human RCT evidenceSmall, older randomized placebo-controlled trials in insomnia with inconsistent results on sleep measures; FDA's July 2026 PCAC briefing recommended against 503A listing, and news reports did not name it among the peptides the committee voted to recommend.

Is DSIP (delta sleep-inducing peptide) legal in the United States?

Regulatory: Nomination withdrawnWADA: WADA prohibited

FDA and compounding status

Not an FDA approved drug. FDA previously placed emideltide (DSIP) in 503A Category 2 and now lists it among bulk drug substances nominated but withdrawn, so it is in no 503A category and outside FDA's interim enforcement policy. FDA nonetheless presented it to the Pharmacy Compounding Advisory Committee on July 24, 2026 and proposed that it not be included on the 503A bulks list. FDA had not posted minutes or a vote result as of the last verification date, and no proposed or final rule has been published. It is not on the 503A bulks list, so compounding pharmacies have no federal basis to compound it, and no 503B pathway has been identified.

WADA status

WADA prohibited. Athletes subject to anti-doping testing should treat this as prohibited at all times unless the current prohibited list says otherwise.

Regulatory timeline

  1. PCAC

    FDA advisory committee reviews DSIP; FDA's briefing recommends against listing

    At the July 24, 2026 meeting, FDA presented delta sleep-inducing peptide (DSIP, emideltide) to its Pharmacy Compounding Advisory Committee and proposed not adding it to the 503A bulks list, citing poor characterization, insufficient safety data, immunogenicity concerns, and lack of evidence of effectiveness. FDA has not posted the vote or minutes. Its nomination was withdrawn, so it remains outside FDA's interim policy.

  2. FDA

    FDA lists BPC-157 and 16 other peptides as withdrawn from 503A Category 2

    FDA's Category 2 page, current as of April 22, 2026, moved BPC-157, AOD-9604, CJC-1295, dihexa, DSIP, epitalon, injectable GHK-Cu, ipamorelin, KPV, LL-37, melanotan II, MOTS-c, PEG-MGF, selank, semax, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) to a list of bulk drug substances nominated but withdrawn by their nominators. Withdrawal takes a substance off Category 2 but does not place it in Category 1, so FDA's interim compounding policy does not cover it, and it is not on the 503A bulks list. Ipamorelin acetate remains in 503B Category 2. Seven of the withdrawn peptides (BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP) were taken to the Pharmacy Compounding Advisory Committee in July 2026.

  3. FDA

    FDA places a batch of nominated peptides in 503A Category 2

    In September 2023 FDA updated its 503A bulk drug substances category lists to place a group of nominated peptides in Category 2, which means FDA identified significant safety risks and the substances may not be used in 503A compounding while the evaluation continues. Kisspeptin-10 and ibutamoren (MK-677) were added on September 29, 2023 and remain in Category 2 on the FDA page current as of April 22, 2026. BPC-157, CJC-1295, ipamorelin, AOD-9604, dihexa, DSIP, epitalon, KPV, MOTS-c, selank, semax, melanotan II, LL-37, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) were also placed in Category 2 under the 503A interim policy; that same page now lists them as nominated but withdrawn (see the April 2026 event). Hexarelin, PNC-27, and 5-amino-1MQ have never appeared on the FDA category lists.

Full tracker for DSIP (delta sleep-inducing peptide) or the category-wide tracker.

Email me when DSIP (delta sleep-inducing peptide)'s status changes

Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.

What published studies of DSIP (delta sleep-inducing peptide) used

Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.

Human trials used intravenous DSIP at approximately 25 nmol/kg (about 0.02 mg/kg) given in the evening for a small number of nights (Schneider-Helmert 1987; Monti 1987). No subcutaneous, intranasal, or oral human dose has been studied.

Routes reported

Routes of administration reported for DSIP (delta sleep-inducing peptide)
#Route
1Intravenous infusion (clinical trials)
2Subcutaneous injection (as sold, no human data)
3Intranasal (as sold, no human data)

What are the side effects and interactions of DSIP (delta sleep-inducing peptide)?

Side effects

Side effects reported for DSIP (delta sleep-inducing peptide)
#Reported side effect
1No adverse effects beyond placebo were reported in the small trials, but total human exposure is a few dozen patients
2Headache and drowsiness reported anecdotally
3Injection site reactions reported anecdotally
4No long term safety data

Interactions

Interactions reported for DSIP (delta sleep-inducing peptide)
#Interaction
1No formal interaction studies exist
2Additive sedation with hypnotics, alcohol, opioids, or benzodiazepines is plausible but untested

Contraindications

Contraindications for DSIP (delta sleep-inducing peptide)
#Contraindication
1Pregnancy and breastfeeding (no data)
2Competitive athletes subject to WADA testing (prohibited under S0)
3Uncontrolled depression or sleep apnea, where an untested sedative peptide can mask treatable causes of poor sleep

How do people access DSIP (delta sleep-inducing peptide) legally?

Typical cost: Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. Not available through licensed compounding or telehealth channels.

Access options

  • Not available

    Not available as an FDA approved product.

  • Not available

    Not on the 503A bulks list: FDA's own July 2026 briefing recommended against listing it, and FDA has not posted the committee's vote.

  • Not available

    Products labeled research use only are unapproved drugs when sold for human use and are not verified for purity.

Access paths are checked against public regulatory records. Products labeled research use only are never listed.

What's actually offered, and what that means for you

FDA has found a compounding pharmacy, clinics, and online sellers offering DSIP anyway. [9] [10]

Being offered does not change the legal status of DSIP (delta sleep-inducing peptide). DSIP (delta sleep-inducing peptide) is not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound it. [5] [11]

What FDA found

  • July 2026: FDA's review found neurology clinics, concierge services, med spas, wellness clinics, and online retailers marketing DSIP injections and nasal sprays, one with a telemedicine consult, and an online clinic that prescribes it. [10]
  • April 2020: FDA named DSIP among the bulk substances a state-licensed 503A pharmacy compounded outside section 503A. [9]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [11] [12] [13] [14] [15] [16]

What that means for you

  • A pharmacy that compounds DSIP (delta sleep-inducing peptide) is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [12] [13]
  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [16]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [17]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [18] [19]
  • Identity, purity, sterility, and dose accuracy can vary from batch to batch. [11]
  • Insurance rarely covers it, so you usually pay cash.
  • For tested athletes, DSIP (delta sleep-inducing peptide) is prohibited under the WADA Prohibited List, whatever the source. Some entries apply only in competition or only to male athletes, so check the section that covers it. [7]

If you're going ahead anyway

These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound DSIP (delta sleep-inducing peptide), with or without a prescription. [5]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [20] [21] [22]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [22] [23] [24]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [16] [25] [26] [27] [28] [29]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [16]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [20]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [24]
  • Pharmacy: Is this made for me on a prescription written in my name? [23]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [22] [24]
  • Prescriber: What is the legal basis for a pharmacy to compound DSIP (delta sleep-inducing peptide)? Is it FDA approved or on the 503A bulks list? [5] [16]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [24]

In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [17]

Frequently asked questions

Is DSIP legal in the United States?

It is not FDA approved, and it cannot currently be compounded (custom-made by a pharmacy). FDA removed DSIP from its 503A Category 2 list (compounding ingredients flagged for significant safety risks) on April 22, 2026, and at the July 2026 Pharmacy Compounding Advisory Committee (FDA's outside expert panel) meeting, FDA's own briefing recommended against adding it to the bulks list of ingredients pharmacies may use. It is not on that list, so a 503A pharmacy has no federal basis to make it. Products sold as research chemicals for human use are unapproved drugs. [5] [6] [8]

Does DSIP work for insomnia or sleep?

The evidence is thin and old. Three small double blind trials from 1987 to 1992 in chronic insomnia found modest short term effects on some sleep measures and none on others, and no trial has been done since. A 2006 review concluded DSIP's role in sleep is unresolved. It has never been tested in the subcutaneous form sold online. [1] [2] [3] [4]

What are the side effects of DSIP?

The small intravenous trials did not report side effects beyond placebo, but fewer than 100 people have received it in published studies and none for more than a few nights. Anecdotal reports mention headache, grogginess, and injection site irritation. There is no long term safety data. [2] [3]

How is DSIP taken?

In the trials it was given intravenously in the evening at about 25 nmol/kg for a few nights. Products sold online are subcutaneous injection vials or nasal sprays, and no human study has used those routes or established a dose for them. [1] [2]

How much does DSIP cost?

No licensed pharmacy channel exists. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. [5] [8]

Is DSIP banned by WADA?

Yes. DSIP has no approval from any government health authority for human use, so it is prohibited at all times under section S0 of the WADA Prohibited List. [7]

Why did FDA recommend against listing DSIP?

At the July 23 to 24, 2026 Pharmacy Compounding Advisory Committee meeting, FDA's own briefing recommended against adding DSIP to the 503A bulks list, as it did for BPC-157, KPV, TB-500, MOTS-c, semax, and epitalon, and FDA has not posted the vote or minutes. The committee's standard is documented safety, effectiveness, and a history of use, and DSIP's human data consist of a few small trials from the 1980s. [4] [6]

DSIP vs epitalon for sleep: which has more evidence?

Neither has a modern randomized trial for sleep. DSIP has three small placebo controlled insomnia trials from decades ago with inconsistent results; epitalon's human data are two Russian melatonin studies whose abstracts do not state the design or sample size. FDA's own July 2026 briefing recommended against listing either one for compounding, which bears on their compounding outlook but not on the strength of their sleep evidence. [3] [6]

Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.

From the blog

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Eur Neurol 1987PubMed 3622582, 1987
  2. [2]Monti JM et al. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. Int J Clin Pharmacol Res 1987PubMed 3583493, 1987
  3. [3]Bes F et al. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology 1992PubMed 1299794, 1992
  4. [4]Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem 2006PubMed 16539679, 2006
  5. [5]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
  6. [6]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
  7. [7]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
  8. [8]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
  9. [9]FDA warning letter 594743, April 1, 2020, to a state-licensed 503A compounding pharmacy (FDA warning letters database)FDA, 2020
  10. [10]FDA briefing document, Pharmacy Compounding Advisory Committee, July 23 to 24, 2026: emideltide (DSIP)-related bulk drug substancesFDA, 2026

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, September 30). DSIP (delta sleep-inducing peptide): evidence, legality, and access. https://peptideagent.ai/peptides/dsip
HTML link
<a href="https://peptideagent.ai/peptides/dsip">DSIP (delta sleep-inducing peptide): evidence, legality, and access</a>, PeptideAgent, updated September 30, 2026.